Xeris Biopharma Expects 2024 Revenue Of $170M-$200M Versus Consensus Of $184.11M; Year-End Cash, Cash Equivalents, And Short-term Investments Of $55M-$75M
Portfolio Pulse from Benzinga Newsdesk
Xeris Biopharma projects its 2024 revenue to be between $170M-$200M, aligning with the consensus estimate of $184.11M. The company also forecasts year-end cash, cash equivalents, and short-term investments to range from $55M to $75M.
March 06, 2024 | 12:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Xeris Biopharma expects its 2024 revenue to be in the range of $170M-$200M, closely matching the consensus estimate of $184.11M. Additionally, it anticipates its year-end cash, cash equivalents, and short-term investments to be between $55M and $75M.
The company's revenue forecast aligns closely with consensus estimates, indicating a positive outlook and potentially reassuring investors. The expected range of year-end financials suggests a stable financial position, which could positively influence investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100